Oncology Institute (NASDAQ:TOI) Price Target Raised to $8.00 at B. Riley Financial

Oncology Institute (NASDAQ:TOI) had its target price upped by B. Riley Financial from $6.00 to $8.00 in a research note published on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other research firms have also weighed in on TOI. BTIG Research reissued a “buy” rating and issued a $7.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oncology Institute in a research note on Wednesday, January 21st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $5.00 target price on shares of Oncology Institute in a report on Monday, March 9th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oncology Institute currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.00.

Oncology Institute Stock Performance

TOI opened at $2.84 on Friday. The stock has a market capitalization of $279.40 million, a price-to-earnings ratio of -5.07 and a beta of 0.14. The company has a fifty day moving average of $3.01 and a 200 day moving average of $3.39. Oncology Institute has a fifty-two week low of $0.63 and a fifty-two week high of $4.88.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. Oncology Institute had a negative net margin of 11.45% and a negative return on equity of 1,527.21%. The business had revenue of $141.96 million for the quarter, compared to analysts’ expectations of $139.78 million.

Insider Activity at Oncology Institute

In other Oncology Institute news, Director Brad Hively sold 13,333 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $3.77, for a total transaction of $50,265.41. Following the transaction, the director directly owned 683,721 shares in the company, valued at $2,577,628.17. This trade represents a 1.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

A number of hedge funds and other institutional investors have recently made changes to their positions in TOI. Kestra Advisory Services LLC purchased a new position in Oncology Institute during the fourth quarter valued at approximately $31,000. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute during the fourth quarter valued at about $36,000. R Squared Ltd purchased a new position in shares of Oncology Institute in the 4th quarter worth approximately $41,000. Prelude Capital Management LLC purchased a new position in shares of Oncology Institute in the 3rd quarter worth approximately $41,000. Finally, ProShare Advisors LLC bought a new position in shares of Oncology Institute during the 2nd quarter worth approximately $25,000. Institutional investors own 36.86% of the company’s stock.

More Oncology Institute News

Here are the key news stories impacting Oncology Institute this week:

• Positive Sentiment: B. Riley raised its price target to $8.00 and put a Buy rating on TOI — the new target implies substantial upside versus recent levels, which can drive buying interest from investors and funds. Benzinga: B. Riley price target raise
• Positive Sentiment: Management reiterated FY‑2026 revenue guidance of $630M–$650M and said it is expanding delegated capitation partnerships — signals that growth and margin‑enhancing contract mix remain intact. MSN: TOI reiterates 2026 guidance
• Positive Sentiment: Q4 results showed record revenue and management highlighted the company’s first profitable quarter on the metrics discussed on the call (growth + improved profitability narrative), supporting the bullish sentiment. GlobeNewswire: Q4 and FY2025 results
• Neutral Sentiment: The company beat consensus for the quarter (revenue ~$142M vs. ~$139.8M est.; GAAP EPS better than expected at a loss of $0.06 vs. $0.08 est.), but details on EPS guidance were sparse in the release. Investors are parsing organic growth vs. one‑time items. MarketBeat: Q4 results & transcript
• Negative Sentiment: Despite the progress, the company still reports negative net margin and a large negative return on equity on reported GAAP metrics — execution risk remains on translating revenue growth into sustained GAAP profitability. MarketBeat: Financial metrics

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.